Bell Asset Management LTD Gilead Sciences, Inc. Transaction History

Bell Asset Management LTD

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $3.67 Million - $4.7 Million	-58,643 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $2.93 Million - $3.22 Million	-47,521 Reduced 44.76%	58,643 $3.81 Million
Q3 2019 Nov 13, 2019	BUY	$62.51 - $69.0 $2.24 Million - $2.47 Million	35,755 Added 50.78%	106,164 $6.73 Million
Q1 2019 Apr 11, 2019	BUY	$62.53 - $70.05 $258,561 - $289,656	4,135 Added 6.24%	70,409 $4.58 Million
Q4 2018 Jan 22, 2019	BUY	$60.54 - $79.0 $482,685 - $629,867	7,973 Added 13.68%	66,274 $4.15 Million

Q3 2018 Oct 29, 2018	BUY	$71.28 - $78.92 $300,017 - $332,174	4,209 Added 7.78%	58,301 $4.5 Million
Q2 2018 Aug 13, 2018	BUY	$64.88 - $75.68 $31,985 - $37,310	493 Added 0.92%	54,092 $3.84 Million
Q4 2017 Feb 14, 2018	BUY	$71.15 - $83.52 $3.81 Million - $4.48 Million	53,599	53,599 $3.84 Million

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $83.6B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Bell Asset Management LTD, based on Form 13F filings with the SEC.

Stay updated on Bell Asset Management LTD with notifications on news.